Skip to main content
. Author manuscript; available in PMC: 2014 Jan 28.
Published in final edited form as: Cancer Lett. 2012 Oct 9;328(2):307–317. doi: 10.1016/j.canlet.2012.10.001

Figure 5. The effect of nilotinib on plasma and tumor concentration of paclitaxel in ABCB1-xenograft model.

Figure 5

Paclitaxel concentration in KB-C2 tumor (box – paclitaxel tumor AUC) A. plasma (box – paclitaxel plasma AUC) B. KB-C2 tumor/plasma AUC ratio C. with or without nilotinib treatment is shown. In the combination group, 75 mg/kg nilotinib was given orally, 1 h before giving 18 mg/kg paclitaxel via tail vein injection. Mice (n=5-6) were euthanized via cardiac puncture at different intervals and tumor and plasma was harvested and stored in -80°. Paclitaxel was quantified as described in materials and methods. Columns, means (n = 3-6); bars, SD. * P < 0.05, compared with only paclitaxel receiving group (unpaired student t-test).